Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Forkhead domain mutations in FOXA1 drive prostate cancer cell progression

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE133455 | GEO | 2019/10/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Forkhead domain mutations in FOXA1 drive prostate cancer progression.

Project description: Not available

| S-EPMC6796877 | biostudies-literature

Forkhead domain mutations in FOXA1 drive prostate cancer cell progression

Project description:Forkhead domain mutations in FOXA1 drive prostate cancer cell progression

| PRJNA551479 | ENA

Distinct structural classes of activating FOXA1 alterations in prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-12-12 | GSE123625 | GEO

Altered chromatin remodeling by FOXA1 mutations promotes androgen independence and prostate cancer aggressiveness

Project description:This SuperSeries is composed of the SubSeries listed below.

2019-11-21 | GSE128884 | GEO

Characterization of FOXA1 mutations in breast cancer

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-11-19 | GSE134657 | GEO

Targeting FOXA1-mediated repression of TGF-β signaling suppresses castration-resistant prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-11-01 | GSE119759 | GEO

FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.

Project description:Mutations in the transcription factor FOXA1 define a unique subset of prostate cancers but the functional consequences of these mutations and whether they confer gain or loss of function is unknown1-9. Here, by annotating the landscape of FOXA1 mutations from 3,086 human prostate cancers, we define two hotspots in the forkhead domain: Wing2 (around 50% of all mutations) and the highly conserved DNA-contact residue R219 (around 5% of all mutations). Wing2 mutations are detected in adenocarcinomas at all stages, whereas R219 mutations are enriched in metastatic tumours with neuroendocrine histology. Interrogation of the biological properties of wild-type FOXA1 and fourteen FOXA1 mutants reveals gain of function in mouse prostate organoid proliferation assays. Twelve of these mutants, as well as wild-type FOXA1, promoted an exaggerated pro-luminal differentiation program, whereas two different R219 mutants blocked luminal differentiation and activated a mesenchymal and neuroendocrine transcriptional program. Assay for transposase-accessible chromatin using sequencing (ATAC-seq) of wild-type FOXA1 and representative Wing2 and R219 mutants revealed marked, mutant-specific changes in open chromatin at thousands of genomic loci and exposed sites of FOXA1 binding and associated increases in gene expression. Of note, ATAC-seq peaks in cells expressing R219 mutants lacked the canonical core FOXA1-binding motifs (GTAAAC/T) but were enriched for a related, non-canonical motif (GTAAAG/A), which was preferentially activated by R219-mutant FOXA1 in reporter assays. Thus, FOXA1 mutations alter its pioneering function and perturb normal luminal epithelial differentiation programs, providing further support for the role of lineage plasticity in cancer progression.

| S-EPMC6661172 | biostudies-literature

Mitochondrial mutations drive prostate cancer aggression.

Project description:Nuclear mutations are well known to drive tumor incidence, aggression and response to therapy. By contrast, the frequency and roles of mutations in the maternally inherited mitochondrial genome are poorly understood. Here we sequence the mitochondrial genomes of 384 localized prostate cancer patients, and identify a median of one mitochondrial single-nucleotide variant (mtSNV) per patient. Some of these mtSNVs occur in recurrent mutational hotspots and associate with aggressive disease. Younger patients have fewer mtSNVs than those who diagnosed at an older age. We demonstrate strong links between mitochondrial and nuclear mutational profiles, with co-occurrence between specific mutations. For example, certain control region mtSNVs co-occur with gain of the MYC oncogene, and these mutations are jointly associated with patient survival. These data demonstrate frequent mitochondrial mutation in prostate cancer, and suggest interplay between nuclear and mitochondrial mutational profiles in prostate cancer.In prostate cancer, the role of mutations in the maternally-inherited mitochondrial genome are not well known. Here, the authors demonstrate frequent, age-dependent mitochondrial mutation in prostate cancer. Strong links between mitochondrial and nuclear mutational profiles are associated with clinical aggressivity.

| S-EPMC5610241 | biostudies-literature

LSD1 promotes castration-resistant prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-06-30 | E-GEOD-77763 | biostudies-arrayexpress

FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2013-02-05 | E-GEOD-39880 | biostudies-arrayexpress